Oxford BioDynamics to expand strategic focus beyond biomarker discovery to development and commercialization of laboratory tests

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups.

Alshaker, H., et. al.,
J Transl Med 19, 46 (2021)

February 2, 2021

https://doi.org/10.1186/s12967-021-02710-y

The Prospective Study of Epigenetic Regulatory Profiles in Sport and Exercise Monitored Through Chromosome Conformation Signatures

Hall, ECR., et. al.,
Genes 2020, 11(8), 905

August 7, 2020

https://doi.org/10.3390/genes11080905

Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies

Hunter, E., et. al.,
Translational Medicine Communications (2020) 5:5

March 25, 2020

https://doi.org/10.1186/s41231-020-00054-1

Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch® epigenetic profiling

Hunter, E., et. al.,
SITC, J. Immunotherapy Cancer 7, 282 (2019) P143.

November 8, 2019

https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P143_multitherapy.pdf

Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch® epigenetic profiling

Hunter, E., et. al.,
SITC, J. Immunotherapy Cancer 7, 282 (2019) P142.

November 8, 2019

https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P142_avelumab.pdf

Ectopic gene deregulations and chromosome conformations: integrating novel molecular testing into clinical applications, from leukemias to gliomas

Grand, FH., et. al.,
Handbook of Biomarkers and Precision Medicine

April 8, 2019

https://www.crcpress.com/Handbook-of-Biomarkers-and-Precision-Medicine/Carini-Fidock-Gool/p/book/9781498762588

Epigenetic chromatin conformation changes in peripheral blood can detect thyroid cancer.

Yan et. al.,
Surgery

November 8, 2018

https://doi.org/10.1016/j.surg.2018.05.081

Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington’s disease.

Salter, M., et. al.,
F1000Research 2018, 7:1757

November 7, 2018

https://doi.org/10.12688/f1000research.15828.1

Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis.

Salter et. al.,
EBioMedicine

June 25, 2018

https://doi.org/10.1016/j.ebiom.2018.06.015

The Chromosomal Conformation Signature: A New Kid on the Block in ALS Biomarker Research?

Poesen, K.
EBioMedicine

June 25, 2018

https://doi.org/10.1016/j.ebiom.2018.06.015